CompletedPhase EARLY_1

The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

Lead sponsor

Adrian Vella

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•Healthy volunteers

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01843881

Org study ID11-007667

Secondary IDR01DK082396

Secondary IDUL1RR024150

Timeline

Milestones

Study first posted2013-05-01estimated

Last update posted2013-12-04estimated

Study start2012-03 (month precision)

Primary completion2013-09actual (month precision)

Study completion2013-12actual (month precision)

Assets

Investigational agents

Avexitide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age20 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

Roux-en-Y Gastric Bypass (RYGB)Subjects:

•Subjects who have undergone RYGB

Inclusion Criteria Healthy Subjects:

•Must match RYGB subjects in age, weight, and gender

•Subjects will be without active systemic illness

Exclusion criteria

all Subjects:

•Subjects <20 years old and >70 years old

•For Female Subjects: positive pregnancy text at the time of enrollment or study

•Subjects with functional or organic bowel symptoms.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.